It was a lacklustre finish to what has been a rather rough trading week for the S&P/ASX 200 Index (ASX: XJO) this Friday.

After a shaky and volatile session that saw the index whipsaw quite a lot, the ASX 200 ended up closing 0.078% lower by the time the markets closed up shop. That leaves the index at 8,786.5 points as we head into the weekend.

This inglorious end to the trading week for ASX investors follows a red night up on Wall Street.

The Dow Jones Industrial Average Index (DJX: .DJI) wasn’t in a good mood, shedding 0.36%.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) fared worse, though, dropping by 0.89%.

But let’s return to the local markets now and see how the various ASX sectors ended their respective weeks today.

Winners and losers

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• ASX 200 drops again. This is what’s starting to worry investors
• ASX 200 energy shares lift as pessimism over Iran war deepens
• Why Newmont, Nuix, PLS, and Vulcan Energy shares are rising today
• This ASX lithium stock is bouncing back today. Here’s why
• 3 ASX 200 shares too cheap to ignore after sell-offs

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Data#3 and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are looking for some big potential returns for your investment portfolio, then it could pay to hear what Morgans is saying about the two ASX 200 shares in this article.

That’s because the broker believes these shares are cheap and have the potential to rise around 50% from where they trade today.

Let’s see what the broker is recommending to clients this week:

Collins Foods Ltd (ASX: CKF)

Morgans thinks this quick service restaurant operator’s shares are undervalued at current levels.

The broker has a buy rating and $12.50 price target on its shares. Based on its current share price of $8.29, this implies potential upside of 50%.

Commenting on its buy recommendation, Morgans said:

We revise our CKF forecasts ahead of the FY26 result in June, trimming underlying NPAT to reflect deferred store openings, reset German acquired store economics, and a lower EU SSS assumption to better capture the Netherlands-skewed mix for FY26, partially offset by a marginal AU SSS upgrade on sustained KFC Australia momentum. We maintain our BUY recommendation and reduce our price target to $12.50 (from $12.70).

Pro Medicus Ltd (ASX: PME)

Another ASX 200 share that Morgans is recommending to clients is health imaging technology company Pro Medicus.

After making adjustments to its financial model for Pro Medicus, the broker has retained its buy rating with a $210.00 price target. Based on its current share price of $138.73, this implies potential upside of 51% for investors between now and this time next year.

Morgans has been impressed with Pro Medicus’ contract wins since the release of its half-year results in February and remains very positive on its long-term growth opportunity. It explains:

In this note, we deploy a new PME model where we have deliberately set a lower bar. Our remodelled estimates prioritise achievability over optimism, staging implementation revenue conservatively and mark FX to spot. We see this as the right framework for a stock where sentiment has been fragile. On the business operations front, the story remains untarnished.

Contract newsflow since February has been exceptional: ~$100m in wins and renewals, all at higher pricing, with cardiology upsell gaining traction. The demand story is not in question. We re-emphasise our positive long-term conviction on the name although lower our valuation to reflect current but potentially fleeting headwinds. Our target price is reduced to A$210 p/s and we retain our Buy recommendation.

The post 2 ASX 200 stocks that could rise 50% appeared first on The Motley Fool Australia.

More reading

• I was going to buy these ASX tech stocks. Now, I’m not so sure
• 3 amazing ASX growth shares that continue to stand out
• Why I’d invest $2,500 in Life360 and Pro Medicus shares today
• What on earth’s going on with Pro Medicus shares?
• Are Pro Medicus shares a buy right now?

Motley Fool contributor James Mickleboro has positions in Collins Foods and Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Collins Foods and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Back in January, I wrote a piece that named two ASX tech stocks as the top of my buy list if the share market experienced a crash in 2026.

Those two ASX tech stocks were TechnologyOne Ltd (ASX: TNE) and Pro Medicus Ltd (ASX: PME). These companies are two of Australia’s finest. Both have consistently delivered for shareholders over recent years and boast enviable stock price trajectories.

At the time, I outlined my view that if these companies descended to a price point that indicated significant potential value, then I would be tempted to load the boat.

However, I must confess that my faith has been shaken.

As I’ve already touched on, both of these companies are proven winners. TechnologyOne prides itself on its enterprise software products, which have proven wildly popular with governments and businesses in Australia and overseas.

Pro Medicus is also in the software space. Its medical imaging services are in high demand worldwide.

Both companies continue to report happy numbers.

For example, in February, Pro Medicus delivered a 29.7% surge in underlying profits for the six months to 31 December 2025 to $90.7 million.

What’s got me sour on these two ASX tech stocks?

So why the loss of faith? Well, it’s to do with artificial intelligence (AI). Yes, we’ve known about the potential upsides, as well as the potential disruption, of AI technology for a while now. That said, it has recently become clearer that enterprise software stocks face a particularly high level of disruptive risk from AI.

Now, I am no AI expert. But I do see the potential for disruption here. AI tools are becoming better and better at solving enterprise problems that (expensive) software currently handles. Anecdotally, I have already heard several stories of AI rendering business software subscriptions redundant.

There’s every chance that TechnologyOne and Pro Medicus will be able to stay ahead of the curve and evolve and adapt to the threats of AI. But I am not certain of that, not enough to bet my dollars on it anyway.

Warren Buffett once said that “I don’t look to jump over seven-foot bars, I look around for one-foot bars that I can step over”. These two ASX tech stocks are looking increasingly tall in this modern age of AI, at least in my eyes. As such, I’ll probably stick to shorter stocks to step over, at least for now.

The post I was going to buy these ASX tech stocks. Now, I’m not so sure appeared first on The Motley Fool Australia.

More reading

• 6 ASX 200 shares downgraded by brokers this week
• 3 amazing ASX growth shares that continue to stand out
• Why I’d invest $2,500 in Life360 and Pro Medicus shares today
• 3 stellar ASX growth shares to buy now with 30% to 70% upside
• What on earth’s going on with Pro Medicus shares?

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Technology One. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It has been another busy week for many of Australia’s top brokers. This has led to a number of broker notes being released.

Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone right now:

DroneShield Ltd (ASX: DRO)

According to a note out of Bell Potter, its analysts have retained their buy rating and $4.80 price target on this counter-drone technology company’s shares. This follows the release of a strong first-quarter update which revealed revenue up 121% on the prior corresponding period. Bell Potter was also pleased to see that SaaS revenue continues to grow strongly and now represents 6.9% of revenue. Looking ahead, the broker believes DroneShield has a market leading offering and a strengthening competitive advantage. This leaves it well-placed ahead of an expected wave of spending on these types of solutions. As a result, Bell Potter believes DroneShield should see material contracts flowing from its $2 billion+ potential sales pipeline over the next three to six months. The DroneShield share price is trading at $3.73 on Friday.

Generation Development Group Ltd (ASX: GDG)

A note out of Morgans reveals that its analysts have retained their buy rating on this diversified financial services company’s shares with a trimmed price target of $6.16. This follows the release of a solid quarterly update earlier this week. Morgans highlights that once again, the Investment Bond business delivered ahead of expectations. However, taking some of the shine off the result was the softer than expected performance from the Evidentia business. And while the latter has caused the broker to trim its earnings forecasts, it remains positive on Generation Development Group. This is largely due to its exposure to structural growth areas, and its strong competitive positioning in these markets. The Generation Development Group share price is fetching $3.54 at the time of writing.

WiseTech Global Ltd (ASX: WTC)

Another note out of Morgans reveals that its analysts have retained their buy rating on this logistics solutions technology company’s shares with a reduced price target of $70.40. Morgans has made significant changes to its technology coverage, lowering valuations to reflect higher discount rates and uncertainty over terminal values due to AI disruption. Despite this, the broker remains very positive on WiseTech Global and has named it as one of its key picks in the sector. The WiseTech Global share price is trading at $44.17 on Friday afternoon.

The post Brokers name 3 ASX shares to buy right now appeared first on The Motley Fool Australia.

More reading

• Up 209%, what’s next for DroneShield shares?
• Could these ASX stocks really be set to double after crashing this week?
• 2 top ASX shares down over 50% to buy now
• 5 ASX 200 shares with renewed buy ratings this week
• Will global defence ASX ETFs keep climbing? Expert

Motley Fool contributor James Mickleboro has positions in WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended Generation Development Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is yet again under pressure on Friday, with weakness across most sectors weighing on the benchmark.

At the time of writing, the ASX 200 is down 0.53% to 8,746 points. The index briefly traded lower earlier in the session, continuing a softer run into the end of the week.

This follows several days of choppy trading, with news headlines starting to play a bigger role in short-term sentiment.

Here’s what is driving the move.

Oil prices are back in focus

One of the main factors sitting over the market is the recent rise in oil prices.

Brent crude has pushed back above US$106 per barrel, holding near recent highs after a sharp rebound over the past week.

That move has been linked to the ongoing tensions in the Middle East, particularly around supply disruptions and shipping risks.

Keep in mind, higher oil prices tend to act as a huge headwind for equity markets.

They feed into inflation expectations and raise concerns around input costs, which can pressure margins across a wide range of sectors.

And that is showing up in today’s session.

Selling spreads across the ASX

The decline is not being driven by a single sector.

More than half of the ASX sectors are trading lower, with weakness across financials, materials, and consumer-facing businesses.

Large-cap banks are mixed, with the S&P/ASX 200 Financials Index (ASX: XFJ) down around 0.3%.

Miners are under pressure, with the S&P/ASX 200 Resources Index (ASX: XRJ) down roughly 0.8% as commodity prices ease.

Lithium companies have also been weaker, following production updates and ongoing pricing uncertainty.

There are still pockets of strength, though.

Energy stocks are outperforming, with the S&P/ASX 200 Energy Index (ASX: XEJ) up around 1.7%, while S&P/ASX 200 Utilities Index (ASX: XUJ) are also higher, gaining roughly 1.6%.

But unfortunately that has not been enough to offset the wider pullback across the index.

Recent momentum starts to fade

Looking at the recent trend, the ASX 200 had been holding up reasonably well through March and early April.

The benchmark index remains up close to 10% over the past 12 months, supported by gains in large-cap stocks and strong performance from key sectors.

However, the past week has seen momentum start to shift.

The index has pulled back from recent highs and is now tracking lower into the end of the week.

Daily moves have also become more volatile, with buying interest starting to fade.

The post ASX 200 drops again. This is what’s starting to worry investors appeared first on The Motley Fool Australia.

More reading

• EVT flags FY26 EBITDA growth amid hotel strength and portfolio changes
• NEXTDC launches $750m wholesale notes to boost growth funding
• Judo Capital reaffirms FY26 profit guidance as lending growth continues
• Newmont declares quarterly dividend for ASX investors
• Fortescue invests $680m in Pilbara Green Energy Project

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NextDC Ltd (ASX: NXT) shares are edging higher again on Friday.

The data centre operator rose 1% to $14.87 during afternoon trade, extending a strong run that has seen the tech stock jump 22% over the past month. Over 12 months, NextDC shares are up 36%, comfortably outperforming the S&P/ASX 200 Index (ASX: XJO), which has gained around 13%.

So what’s behind the latest move?

Multi-billion dollar funding

The catalyst is fresh funding – and plenty of it.

NextDC announced on Friday that it has successfully priced and allocated a $750 million wholesale subordinated notes offer. The deal lifts its pro forma liquidity, including cash and undrawn facilities, to around $6.6 billion. That’s a big number, and investors interested in NextDC shares are paying attention.

The capital raise forms part of NextDC’s broader $2.2 billion funding plan. It follows on from a recent entitlement offer and a $1.7 billion hybrid securities deal, completing a multi-pronged strategy to secure capital for growth. In simple terms, the company is loading up the balance sheet to fund its next phase.

Surging demand for data centres

That matters because NextDC operates in one of the fastest-growing segments of the market. Demand for data centres continues to surge, driven by cloud computing, artificial intelligence, and digital infrastructure needs across Australia and the Asia-Pacific region. To keep up, the company needs scale, and scale requires capital.

This latest funding round strengthens and diversifies its financing base. The subordinated notes sit below senior debt but above hybrid securities and equity, adding another layer to its capital structure. While the notes won’t be listed on the ASX and are aimed at wholesale investors, they play an important role in improving financial flexibility.

Record capacity locked in

The result is a stronger position to execute. With $6.6 billion in available liquidity, NextDC shares now have significant firepower to fund major data centre developments, support expansion projects, and respond to new opportunities as they arise.

Importantly, this comes at a time when demand is already building. The company has flagged record contracted utilisation across its portfolio, suggesting existing capacity is being filled quickly.

That creates a clear runway for growth.

What next for NextDC shares?

Of course, there are risks for NextDC shares. Large-scale infrastructure projects require significant upfront investment, and returns can take time to materialise. Higher interest rates and funding costs also remain a factor, particularly as the company continues to expand.

But for now, the market appears focused on the positives.

Strong demand, a clear growth strategy, and a well-funded balance sheet are combining to support sentiment. Investors are backing NextDC’s ability to execute, and today’s update reinforces that confidence.

If the company continues to deliver on its expansion plans, this funding boost could prove to be a key catalyst for the next leg of growth.

The post NextDC just raised $750 million, here’s why the shares are climbing appeared first on The Motley Fool Australia.

More reading

• NEXTDC launches $750m wholesale notes to boost growth funding
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: NextDC, Hub24, PLS Group shares
• NextDC shares rocket 27% higher: Buy, hold or sell?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are in the red for a fourth consecutive day, down 0.46% to 8,752.8 points.

The world is waiting for a fresh round of negotiations between the US and Iran to begin, as the global oil shock continues.

Meanwhile, the International Monetary Fund has warned of a global recession given the long-tail impact of energy supply shocks.

Amid this ongoing turmoil, brokers have reduced their ratings on six ASX 200 shares this week.

Let’s take a look.

Macquarie Group Ltd (ASX: MQG)

The Macquarie share price is $231.83, up 0.5% today.

Over the past month, this ASX 200 bank share has lifted substantially, up 19%.

UBS downgraded Macquarie shares to a hold rating yesterday.

The broker considers the stock almost fully valued, given its 12-month price target of $235.

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is 7% lower on Friday at $4.91.

This ASX 200 healthcare share has skyrocketed 1,650% over 12 months.

Jefferies downgraded 4DMedical shares to a hold rating yesterday.

However, the broker believes this stock’s value can continue to grow.

Its 12-month price target is $5.90, implying a potential 17% capital gain ahead.

QBE Insurance Group Ltd (ASX: QBE)

The QBE share price is $22.39, up 0.09% today.

The ASX 200 insurance share has lifted 13% in the year to date (YTD).

Macquarie downgraded QBE shares to a hold rating with a $25.10 price target on Friday.

Sandfire Resources Ltd (ASX: SFR)

The Sandfire Resources share price is $17.26, up 0.2% today.

The ASX 200 copper share has experienced a remarkable run over the past 12 months, rising 73%.

The copper commodity price climbed 42% in 2025 due to rising demand amid the green energy transition.

Sandfire Resources shares reached an all-time high of $21.75 per share in January.

Copper was sold off alongside other metals in February but has rebounded strongly since mid-March.

UBS downgraded Sandfire Resources shares to a sell rating today.

The broker reduced its 12-month price target from $17.70 to $16.75.

TechnologyOne Ltd (ASX: TNE)

The TechnologyOne share price is $28.64, down 3.8% today.

TechnologyOne lost a quarter of its valuation amid the tech wreck that began in 1H FY26.

The ASX 200 tech share is down 26% over the past six months but has rallied 4.5% this month amid a sector turnaround.

Morgans downgraded TechnologyOne shares to a hold rating today.

The broker has a price target of $31.20, implying a potential 9% upside ahead.

Reece Ltd (ASX: REH)

The Reece share price is $13.63, up 1% today.

This ASX 200 industrial share is down 12% year over year, but has lifted 13.6% over the past six months.

Morgans downgraded Reece shares to a hold rating today.

The broker reduced its 12-month price target from $17.70 to $14.10.

This still suggests a near-5% upside ahead.

The post 6 ASX 200 shares downgraded by brokers this week appeared first on The Motley Fool Australia.

More reading

• 3 ASX shares I’d buy if the market dropped again
• Here are the top 10 ASX 200 shares today
• Sandfire Resources lifts cash and revenue in March quarter update
• What are experts saying about these red hot ASX 200 shares?
• 3 stellar ASX growth shares to buy now with 30% to 70% upside

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and Technology One. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

With just a few hours of trade left in the week, the S&P/ASX 200 Index (ASX: XJO) is down 2.2% since last Friday’s close, despite the best lifting efforts of these three surging ASX 200 stocks.

One of this week’s top performers provides building materials, one is a global wine maker, and the third earns its keep providing residential aged care.

Here’s how these ASX shares have managed to charge higher in this week’s sinking market.

ASX 200 stocks jumping in this week’s sliding market

First up, we have James Hardie Industries PLC (ASX: JHX).

Shares in the building materials company closed last Friday at $28.04 and are currently trading at $30.95 apiece. That sees this ASX 200 stock up 10.4% for the week.

There was no price-sensitive news from James Hardie this week. But after hitting four-month lows of $26.10 a share on 31 March, investors appear to believe the stock has been oversold.

This brings us to our second outperformer of the week, Treasury Wine Estates Ltd (ASX: TWE) shares.

Shares in the global wine company closed last week at $4.01 and are currently trading at $4.53 each, putting this ASX 200 stock up 13.0%.

Treasury Wine shares closed up a whopping 16.5% on Wednesday after the company announced its transition to a new regional operating model.

Judging by the share price action, investors clearly approved of the move, which is intended to improve operational efficiency for the struggling wine distributor.

Treasury Wine will transition to its new regional operating model on 1 October. It will then operate four regional divisions: The Americas, Australia and New Zealand (ANZ), Europe, Greater China, and Emerging Markets (Rest of Asia, Middle East and Africa).

“We are reshaping TWE to drive clearer accountability for performance and to enable faster, more market-connected decision-making as a foundation for consistent depletions growth,” Treasury Wine CEO Sam Fischer said.

Leading the charge

Moving on, the top performing ASX 200 stock on my list for this week is Regis Healthcare Ltd (ASX: REG).

Shares in the residential aged care provider closed last Friday at $5.89 and are currently trading for $6.69 apiece. That puts Regis Healthcare shares up 13.6% in this week’s retreating market.

Shares in the ASX 200 healthcare stock closed up 16.4% on Thursday.

While there was no direct price-sensitive news from the company, the Motley Fool’s Cameron England noted that the surge appears to be driven by pending changes to how the Federal government funds residential aged care.

On Wednesday, health minister Mark Butler announced that the government would spend an additional $3 billion to provide more aged care beds and improve overall care for older Australians.

The post 3 ASX 200 stocks storming higher in this week’s sinking market appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 shares too cheap to ignore after sell-offs
• 2 ASX 200 shares newly upgraded this week
• Why is everyone buying this beaten-down ASX wine stock now?
• A Budget announcement has put a rocket under this ASX aged care provider’s shares
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Tetratherix Ltd (ASX: TTX) recently updated shareholders with its quarterly report, which broker Morgans says shows the ASX biotech company continues to tick off key milestones towards commercialisation.

Morgans has this week issued a new research report to its clients, slightly reducing its price target on Tetratherix shares, which we’ll get to later.

Progress on several fronts

So what did the company say this week?

Tetratherix’s key technology is a fluid matrix that can be used in regenerative medicine across multiple applications.

Chief executive Will Knox said in this week’s statement to the ASX that the third quarter was “another strong quarter for Tetratherix as we continued to deliver against key commercial, clinical and strategic milestones”.

He added:

We confirmed readiness to commercialise Tegenix through a global quality and supply agreement with Henry Schein. We also expanded into precision medicine with STEPP, our drug‑delivery platform that has been under stealth development for more than five years. This was folowed by an exclusive R&D agreement with Superpower, under which Tetratherix wil receive licence fees of US$3 milion per year for up to 10 years, together with ongoing purchases of STEPP to support R&D formulation for the US market.

Mr Knox said the company also advanced multiple clinical programs, with encouraging results across tissue healing, “including positive outcomes from the TetraDerm Cohort 1 and 2 studies, and [the company] accelerated the Tutelix pivotal trial program following the successful Series A capital raise by our joint‑venture partner”.

The company was also expecting Food & Drug Administration clearance for its bone regeneration technology this calendar year.

Shares looking cheap

The analyst team at Morgans agreed it was a strong quarter, “achieving multiple clinical, commercial and operational milestones as it advances toward commercialisation”.

The broker said:

Using its innovative Tetramatrix platform technology TTX can develop solutions for multiple medical conditions. TTX is looking to partner with specialist companies to assist with clinical trial, regulatory approvals and market access. We use a discounted cash flow method to value TTX at $6.84. We have set the target price at the same level. We have a speculative buy recommendation on TTX.

Morgans said the company had multiple catalysts for a share price rerating, although it cautioned that positive clinical trial results were not certain and navigating regulatory pathways can be complex.

If the share price were to hit Morgans’ price target, it would be a 45.8% return from the current level of $4.69.

Tetratherix is currently valued at $126.9 million.

The post This ASX biotech stock could deliver 40%-plus returns Morgans says appeared first on The Motley Fool Australia.

More reading

• 6 ASX 200 shares downgraded by brokers this week
• 3 ASX 200 stocks storming higher in this week’s sinking market
• Why Brainchip, Fortescue, IGO, and Life360 shares are tumbling today
• 3 ASX 200 blue-chip shares I’d buy with $5,000 in May
• ASX 200 energy shares lift as pessimism over Iran war deepens

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is having a poor finish to the week. In afternoon trade, the benchmark index is down 0.5% to 8,751.3 points.

Four ASX shares that are falling more than most today are listed below. Here’s why they are tumbling:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 3% to 15 cents. This follows the release of another disappointing update from the struggling semiconductor company. For the three months ended 31 March, Brainchip recorded customer cash inflows of US$700,000. However, this couldn’t stop the company from recording an operating cash outflow of US$5.3 million for the three months. This led to its cash balance reducing to US$25.3 million from US$31.7 million.

Fortescue Ltd (ASX: FMG)

The Fortescue share price is down 5% to $19.93. For the third quarter of FY 2026, Fortescue reported total iron ore shipments of 48.4 million tonnes (Mt). This was below consensus estimates of approximately 49Mt, which may have disappointed investors. Fortescue Metals and Operations CEO, Dino Otranto, was pleased with the quarter. He said: “We delivered a solid quarter, contributing to record shipments of 148.7 million tonnes for the nine months to March. That reflects a significant effort from the team right across the business.” Fortescue also separately announced that it has approved a US$680 million investment to expand its green energy capacity in the Pilbara.

IGO Ltd (ASX: IGO)

The IGO share price is down 15% to $7.28. This battery materials company’s shares have been sold off following the release of its quarterly update. Although it posted a 45% increase in group sales revenue to $119.7 million, the market appears disappointed with an update on its guidance. IGO has updated full-year guidance for Greenbushes spodumene production to 1,375kt to 1,425kt (down from 1,500kt to 1,650kt). IGO’s CEO, Ivan van Vella, said: “Fundamental changes to operating approaches and systems take time to be effective and improvements are typically not linear. Greenbushes is a world-class asset and generated 75% EBITDA margin this quarter. I am confident the work underway will deliver the required performance and overall value optimisation.”

Life360 Inc (ASX: 360)

The Life360 share price is down 4% to $20.89. This follows another selloff of software stocks on Wall Street overnight. The catalyst for this may have been the release of GPT-5.5 by ChatGPT owner OpenAI. It stated: “We’re releasing GPT‑5.5, our smartest and most intuitive to use model yet, and the next step toward a new way of getting work done on a computer.”

The post Why Brainchip, Fortescue, IGO, and Life360 shares are tumbling today appeared first on The Motley Fool Australia.

More reading

• Why Newmont, PLS and Fortescue shares are grabbing headlines on Friday
• Guess which ASX iron ore stock could rise 85% (hint, not Fortescue shares)
• IGO shares sink 14%. Here’s what just spooked investors?
• Why are Fortescue shares falling today?
• Fortescue invests $680m in Pilbara Green Energy Project

Motley Fool contributor James Mickleboro has positions in Life360. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.